THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC - TO DEVELOP A NOVEL MODULATOR TARGETING PROTEOSTASIS FOR THE TREATMENT OF M. TUBERCULOSIS.

PIID: 75N93024C00008Solicitation ID: HHS-NIH-NIAID-BAA2023-1

Signed Date: Jan 6, 2026Effective Date: May 10, 2024End Date: Closes in 58 days

Award $

$2.5M

Vendor

THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

NAICS

541715

Signed Date

Jan 6, 2026

Key Details

Dollars Obligated

$2.5M

Base & All Options

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Number of Offers

Place of Performance

NEW YORK, NY, 100051338, CD-NY-10

TO DEVELOP A NOVEL MODULATOR TARGETING PROTEOSTASIS FOR THE TREATMENT OF M. TUBERCULOSIS.

On Jan 6, 2026, Department of Health and Human Services obligated $2,475,623 to THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC for to develop a novel modulator targeting proteostasis for the treatment of m. tuberculosis.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition with 18 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in NEW YORK, NY. The contract is scheduled through Nov 9, 2026 — approximately 2 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.